Information

Search millions of cases and get court filings, fast docket alerts, and case analytics.

Request a Demo or create your account.

Lawyer? Your firm may have a group account, ask us and we'll let you know.

Click below for detailed party information:

Patent Owner

Replimune Limited

Petitioners

Transgene Bioinvent International

alt+h	Toggle this page.
alt+u	Toggle Upcoming Events view.
alt+e	Export the docket to Excel.
Filtering / Searching the Docket
ctrl+f	Filter the docket.
ctrl+shift+f	Search docket and documents.
alt+s	Toggle between "Show Only" filtering modes.
alt+d, ctrl+f	System ctrl+f
escape	Clear while in docket filter.
Interactive Timeline
alt+t	Show / re-center case timeline.
alt+↑	Zoom in
alt+↓	Zoom out
alt+←	Pan left
alt+→	Pan right

Transgene v. Replimune Limited

PGR2022-00014 | Patent Trial and Appeal Board

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.

Filed Dec. 15, 2021

Terminated May 25, 2023

Judges Christopher Paulraj, Jamie Wisz, and Ryan Flax

Case Type Post Grant Review

Status Final Written Decision

Challenged Patent 16/68,830

Patent No. 10,947,513 assignments

Tech Center 1600

Art Unit 1648

Inventors Robert COFFIN

Last Updated: 1 month, 2 weeks ago

Filing Date	#	Filing and Exhibits
Entries matching. Show All.
5/25/2023	05-25-2023-Board	Event: Final Written Decision (No Claims Cancelled) Board Final Written Decision: original 38: Final Written Decision: original
5/22/2023	05-22-2023-Board	Board Other: Hearing transcript 37: Other: Hearing transcript
5/19/2023	05-19-2023-Board	Board Order: Other 36: ORDER Conduct of the Proceeding 37 C.F.R. § 42.5
3/31/2023	03-31-2023-Petitioner	Petitioner Other: other 34: Petitioners Additional Briefing Regarding Xerox and Intel
3/31/2023	03-31-2023-Patent_Owner	Patent Owner Other: other 35: Patent Owner's Supplemental Brief Regarding Xerox and Intel
3/20/2023	03-20-2023-Board	Board Order: on Motion 33: ORDER Conduct of the Proceeding 37 C.F.R. sec 42.5
3/14/2023	03-14-2023-Petitioner	Petitioner Exhibit 1107: Exhibit 1107 - Petitioners' Demonstrative Exhibits
3/14/2023	03-14-2023-Patent_Owner	Patent Owner Exhibit 2024: Exhibit 2024 - Patent Owner's Demonstrative Exhibits
3/9/2023	03-09-2023-Board	Board Notice: Other 32: LEAP Practitioner Request and Verification Form (Patent Owner)
2/22/2023	02-22-2023-Petitioner	Petitioner Motion: Other 31: Petitioners Unopposed Motion for Refund of Fees
2/13/2023	02-13-2023-Board	Board Order: Other 30: Order: Setting Oral Argument
2/10/2023	02-10-2023-Petitioner	Petitioner Other: Refund request 29: Petitioners' Request for Refund
2/3/2023	02-03-2023-Petitioner	Petitioner Other: other 27: Petitioners' Request for Oral Argument
2/3/2023	02-03-2023-Patent_Owner	Patent Owner Motion: Oral Hearing Request 28: Patent Owner's Request for Oral Argument
2/1/2023	02-01-2023-Patent_Owner	Patent Owner Other: other 26: Patent Owner Sur-Reply
12/20/2022	12-20-2022-Petitioner	Petitioner Pet Reply to PO Resp 24: Petitioners' Reply PGR2022-00014 Petitioner Notice: Exhibit list 25: Petitioners' Exhibit List as of December 20, 2022 Petitioner Exhibit 1101: Ex 1101 Guo et al 2017 Petitioner Exhibit 1102: Ex 1102 Guse et al 2010 Petitioner Exhibit 1103: Ex 1103 Rintoul et al 2011 Petitioner Exhibit 1104: Ex 1104 Chiocca Deposition Notice Petitioner Exhibit 1105: Ex 1105 Yamamoto et al 2006 Petitioner Exhibit 1106: Ex 1106 Chiocca Deposition Transcript with Errata
11/8/2022	11-08-2022-Petitioner	Petitioner Notice: Notice of deposition 23: Notice of Deposition of E. Antonio Chiocca M.D., Ph.D.
9/28/2022	09-28-2022-Patent_Owner	Patent Owner Response 22: Patent Owner Response Patent Owner Exhibit 2008: EX2008 - US20220056480A1 Patent Owner Exhibit 2009: EX2009 - Declaration of E. Antonio Chiocca Patent Owner Exhibit 2010: EX2010 - Semmrich Poster Patent Owner Exhibit 2011: EX2011 - Semmrich 2022 Patent Owner Exhibit 2012: EX2012 - Zitvogel PH Excerpt Patent Owner Exhibit 2013: EX2013 - Thomas Patent Owner Exhibit 2014: EX2014 - Kaufman 2015 Patent Owner Exhibit 2015: EX2015 - Silvestre PH Excerpt Patent Owner Exhibit 2016: EX2016 - 513 PH (4-30-2020 Response) Patent Owner Exhibit 2017: EX2017 - Rojas 2015 Patent Owner Exhibit 2019: EX2019 - Yang Patent Owner Exhibit 2020: EX2020 - Kleinpeter 2016 Patent Owner Exhibit 2021: EX2021 - Transcript of John C. Bell Patent Owner Exhibit 2022: EX2022 - Lun 2009 Patent Owner Exhibit 2023: EX2023 - Chiocca E. Antonio CV
9/15/2022	09-15-2022-Patent_Owner	Patent Owner Notice of Deposition 21: Patent Owner's Notice of Deposition of John C. Bell
7/14/2022	07-14-2022-Patent_Owner	Patent Owner Notice 20: Notice of Joint Stipulation to Modify Schedule
7/1/2022	07-01-2022-Patent_Owner	Patent Owner Objection 19: Patent Owner's Objections to Evidence
6/22/2022	06-22-2022-Petitioner	Petitioner Notice 18: Petitioners' Updated Mandatory Notices as of June 22, 2022
6/16/2022	06-16-2022-Board	Event: Petition Institution (Granted) Board Institution Decision: Grant 16: Institution Decision: Grant Board Order: Other 17: Order: SCHEDULING ORDER
6/1/2022	06-01-2022-Board	Board Order: Other 15: Order: Panel Change Order
4/19/2022	04-19-2022-Patent_Owner	Patent Owner Other (Not for motions) 13: Patent Owner's List of Improper Preliminary Reply Arguments Patent Owner Exhibit List 14: Patent Owner's Updated Exhibit List Patent Owner Exhibit 2007: Exhibit 2007 - Email dated 19 April 2022 from Board to A. Stein
4/14/2022	04-14-2022-Petitioner	Petitioner Reply 12: Petitioners' Reply to Patent Owner's Preliminary Response
4/11/2022	04-11-2022-Patent_Owner	Patent Owner Exhibit List 11: Patent Owners Updated Exhibit List Patent Owner Exhibit 2006: Exhibit 2006 - Rough Transcript of 6 April 2022 Conference Call with the Board
4/8/2022	04-08-2022-Board	Board Notice: Other 10: ERRATUM
4/6/2022	04-06-2022-Board	Board Order: on Motion 9: ORDER Conduct of the Proceeding Granting-In-Part Petitioners Request to File a Pre-Institution Reply 37 C.F.R. sec 42.5
3/22/2022	03-22-2022-Patent_Owner	Event: Preliminary Response Patent Owner Preliminary Response 8: Patent Owner's Preliminary Response Patent Owner Exhibit 2001: Exhibit 2001 - Disclaimer Patent Owner Exhibit 2002: Exhibit 2002 - Jan 13, 2021 Examiner Interview Summary Patent Owner Exhibit 2003: Exhibit 2003 - Jan 29, 2021 Applicant Interview Summary Patent Owner Exhibit 2004: Exhibit 2004 - Feb 1, 2021 Notice of Allowance Patent Owner Exhibit 2005: Exhibit 2005 - Third Party Observations
1/5/2022	01-05-2022-Patent_Owner	Patent Owner Mandatory Notice 6: Patent Owner Replimune Limited's Mandatory Notice Patent Owner Power of Attorney 7: Patent Owner Replimune Limited's Power of Attorney
12/22/2021	12-22-2021-Board	Board Notice: Notice filing date accorded 5: Notice: Notice filing date accorded
12/15/2021	12-15-2021-Petitioner	Event: Petition Petitioner Petition 1: Petition for Post-Grant Review of U.S. Patent No. 10,947,513 Petitioner Power of Attorney 2: Transgene Power of Attorney Petitioner Power of Attorney 3: BioInvent International AB Power of Attorney Petitioner Exhibit List 4: Petitioner's Exhibit List as of December 15, 2021 Petitioner Exhibit 1001: U.S. Patent No. 10,947,513 Petitioner Exhibit 1002: U.S. Patent No. 10,555,981 Petitioner Exhibit 1003: Du et al., Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers, 21 CANCER GENE THERAPY 340-348 (2014) Petitioner Exhibit 1004: U.S. Patent No. 10,765,710 Petitioner Exhibit 1005: Choi et al., Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect, 13 GENE THERAPY 1010-1020 (2006) Petitioner Exhibit 1006: Curriculum vitae of John C. Bell, Ph.D. Petitioner Exhibit 1007: Declaration of John C. Bell, Ph.D. dated December 14, 2021 Petitioner Exhibit 1008: British Patent Application GB 1600380 Petitioner Exhibit 1009: British Patent Application GB 1600381 Petitioner Exhibit 1010: British Patent Application GB 1600382 Petitioner Exhibit 1011: Declaration of Dr. Sylvia D. Hall-Ellis dated November 29, 2021 Petitioner Exhibit 1012: Curriculum vitae of Dr. Sylvia D. Hall-Ellis Petitioner Exhibit 1013: International Patent Application PCT/GB2017/050038 Petitioner Exhibit 1014: Published International Patent Application WO 2017/118866 Petitioner Exhibit 1015: Kaufman et al., Oncolytic viruses: a new class of immunotherapy drugs, 14 CANCER IMMUNOTHERAPY 642-662 (September 2015) Petitioner Exhibit 1016: Amendment filed on February 26, 2020 in U.S. Patent Application Serial No. 16/068,830 Petitioner Exhibit 1017: Notice of Allowance mailed on November 3, 2020, in U.S. Patent Application Serial No. 16/068,830 with attached Interview Summary Petitioner Exhibit 1018: Information Disclosure Statement filed on October 16, 2018, in U.S. Patent Application Serial No. 16/068,830 Petitioner Exhibit 1019: Notice of Allowance mailed on December 23, 2020, in U.S. Patent Application Serial No. 16/068,830 with attached PTO forms PTO-1449 Petitioner Exhibit 1020: Notice of Allowance mailed on December 29, 2020, in U.S. Patent Application Serial No. 16/068,830 with attached PTO forms PTO-1449 Petitioner Exhibit 1021: Excerpts from S. Baron (Ed.), MEDICAL MICROBIOLOGY, 4th. Ed., University of Texas Medical Branch at Galveston (1996) Petitioner Exhibit 1022: Species list extracted from International Committee on Taxonomy of Viruses (ICTV) Master Species List (July 20, 2021), available at https://talk.ictvonline.org/taxonomy/vmr/ Petitioner Exhibit 1023: Output from the National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI) Taxonomy Browser searches for select viruses (performed Nov. 3, 2021), available at https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Root Petitioner Exhibit 1024: List of known isolates within each virus family extracted from NCBI Taxonomy Browser Output of Ex. 1023 Petitioner Exhibit 1025: Herpesviridae Information from Virus Pathogen Resource (ViPR) retrieved on Nov. 4, 2021, available at https://www.viprbrc.org/brc/aboutPathogen.spg?decorator=herpes Petitioner Exhibit 1026: Oliveira et al., Poxvirus Host Range Genes and Virus-Host Spectrum: A Critical Review, 9(11) VIRUSES 2017 331 (Nov. 7, 2017) Petitioner Exhibit 1027: Saha et al., The Adenovirus Genome Contributes to the Structural Stability of the Virion, 6(9) VIRUSES 2014 3563-3583 (Sep. 24, 2014) Petitioner Exhibit 1028: Balvay et al., Translational control of retroviruses, 5 NATURE REVIEWS MICROBIOLOGY 128-140 (Feb. 2007) Petitioner Exhibit 1029: Compilation of Virus Information from Swiss Institute of Bioinformatics retrieved on Nov. 3, 2021, available at https://viralzone.expasy.org/ Petitioner Exhibit 1030: Reoviridae Information from Virus Pathogen Resource (ViPR) retrieved on Nov. 4, 2021, available at https://www.viprbrc.org/brc/aboutPathogen.spg?decorator=reo Petitioner Exhibit 1031: Summary of Characteristics of Commercial Viral Vectors Petitioner Exhibit 1032: van den Wollenberg et al., Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike, 22 GENE THERAPY 267-279 (2015) Petitioner Exhibit 1033: Majid et al., Recombinant Vesicular Stomatitis Virus (VSV) and Other Strategies in HCV Vaccine Designs and Immunotherapy. Tan SL, (Ed.) HEPATITIS C VIRUSES: GENOMES AND MOLECULAR BIOLOGY, Ch. 15. Norfolk (UK): Horizon Bioscience (2006) Petitioner Exhibit 1034: Jacobs et al., HSV-1 based vectors for gene therapy of neurological diseases and brain tumors Part II Vector Systems and Applications, 1(5) NEOPLASIA 402-416 (November 1999) Petitioner Exhibit 1035: Ho et al., Unconventional viral gene expression mechanisms as therapeutic targets, 593 NATURE 362-371 (May 2021) Petitioner Exhibit 1036: Salzberg, Open questions: How many genes do we have? 16 BMC BIOLOGY 94 (August 20, 2018) Petitioner Exhibit 1037: Hillier et al., Genomics in C. elegans: so many genes, such a little worm, 15 GENOME RESEARCH 1651-60 (2005) Petitioner Exhibit 1038: Lundstrom, New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy, 12 BIOLOGICS: TARGETS AND THERAPY 43-60 (2018) Petitioner Exhibit 1039: Liu et al., ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties, 10 GENE THERAPY 292-303 (2003) Petitioner Exhibit 1040: Ma et al., Oncolytic herpes simplex virus and immunotherapy, 19 BMC IMMUNOLOGY 40 (2018) Petitioner Exhibit 1041: Singh et al., Oncolytic viruses & their specific targeting to tumour cells, 136 INDIAN J. MED. RES. 571-584 (October 2012) Petitioner Exhibit 1042: Yang et al., Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters, 447(1-2) VIROLOGY 213-220 (December 2013) Petitioner Exhibit 1043: Riedel et al., Components and Architecture of the Rhabdovirus Ribonucleoprotein Complex, 12(9) VIRUSES 2020 959 (August 2020) Petitioner Exhibit 1044: Dikstein, The unexpected traits associated with core promoter elements, 2(5) TRANSCRIPTION 201-206 (September 2011) Petitioner Exhibit 1045: Willemsen and Zwart, On the stability of sequences inserted into viral genomes, 5(2) VIRUS EVOLUTION vez045 (July 2019) Petitioner Exhibit 1046: Brochu-Lafontaine and Lemay, Addition of exogenous polypeptides on the mammalian reovirus outer capsid using reverse genetics, 179 J. VIROL. METHODS 342-350 (2012) Petitioner Exhibit 1047: Belsham and Sonenberg, RNA-protein interactions in regulation of picornavirus RNA translation, 60(3) MICROBIOLOGICAL REVIEWS 499-511 (September 1996) Petitioner Exhibit 1048: Donovan-Banfield et al., Deep splicing plasticity of the human adenovirus type 5 transcriptome drives virus evolution, 3 COMMUNICATIONS BIOLOGY (2020) 124 Petitioner Exhibit 1049: Yen et al., Vaccinia virus infection & temporal analysis of virus gene expression: Part 2, 2009(26) J. VIS. EXP. 1169 (April 2009) Petitioner Exhibit 1050: Wertz et al., Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression, 76(15) J. VIROL. 7642-50 (August 2002) Petitioner Exhibit 1051: Bett et al., Packaging capacity and stability of human adenovirus type 5 vectors, 67(10) J. VIROL. 5911-21 (October 1993) Petitioner Exhibit 1052: Malhotra et al., Use of an Oncolytic Virus Secreting GM-CSF as Combined Oncolytic and Immunotherapy for Treatment of Colorectal and Hepatic Adenocarcinomas, 141(4) SURGERY 520-529 (April 2007) Petitioner Exhibit 1053: Engeland et al., CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy, 22(11) MOLECULAR THERAPY 1949-59 (November 2014) Petitioner Exhibit 1054: Guedan et al., GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution, 19 GENE THERAPY 1048-57 (2012) Petitioner Exhibit 1055: Fu et al., Expression of a Fusogenic Membrane Glycoprotein by an Oncolytic Herpes Simplex Virus Potentiates the Viral Antitumor Effect, 7(6) MOLECULAR THERAPY 748-754 (June 2003) Petitioner Exhibit 1056: Nakamori et al., Potent Antitumor Activity After Systemic Delivery of a Doubly Fusogenic Oncolytic Herpes Simplex Virus Against Metastatic Prostate Cancer, 60 THE PROSTATE 53-60 (2004) Petitioner Exhibit 1057: Ebert et al., Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer, 64 CANCER RESEARCH 3265-3270 (May 2004) Petitioner Exhibit 1058: Gomez-Trevino et al., Effects of adenovirus-mediated SV5 fusogenic glycoprotein expression on tumor cells, 5 J. GENE MED. (2003) 483-492 Petitioner Exhibit 1059: Sharp and Li, The codon adaptation index - a measure of directional synonymous codon usage bias, and its potential applications, 15(3) NUCLEIC ACIDS RESEARCH 1281-95 (1987) Petitioner Exhibit 1060: Wennier et al., Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy, 13(9) CURR. PHARM. BIOTECHNOL. 1817-33 (July 2012) Petitioner Exhibit 1061: Le Boeuf et al., Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing, 18(5) MOLECULAR THERAPY 888-895 (May 2010) Petitioner Exhibit 1062: Rojas et al., Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy, 21(24) CLIN. CANCER RES. 5543-51 (December 2015) Petitioner Exhibit 1063: Ishihara et al., Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor (August 2014) Petitioner Exhibit 1064: John et al., Oncolytic Virus and Anti4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer, 72(7) CANCER RESEARCH 1651-60 (April 2012) Petitioner Exhibit 1065: Deguchi et al., Combination of the Tumor Angiogenesis Inhibitor Bevacizumab and Intratumoral Oncolytic Herpes Virus Injections as a Treatment Strategy for Human Gastric Cancers, 59(118) HEPATOGASTROENTEROLOGY 1844-50 (September 2012) Petitioner Exhibit 1066: Tan et al., Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft, 136 INT. J. CANCER 1718-30 (2015) Petitioner Exhibit 1067: Fukuhara et al., Triple Gene-Deleted Oncolytic Herpes Simplex Virus Vector Double-Armed with Interleukin 18 and Soluble B7-1 Constructed by Bacterial Artificial Chromosome-Mediated System, 65(23) CANCER RES. 10663-68 (December 2005) Petitioner Exhibit 1068: Lee et al., Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1in an Immunocompetent Murine Model, 12(19) CLIN. CANCER RES. 5859-68 (October 2006) Petitioner Exhibit 1069: Carter et al., Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes, 110(31) PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES 12744-49 (July 2013) Petitioner Exhibit 1070: Published International Patent Application WO 2006/048749 Petitioner Exhibit 1071: U.S. Patent No. 9,487,581 Petitioner Exhibit 1072: Danthinne and Imperiale, Production of first generation adenovirus vectors: a review, 7 GENE THERAPY 1707-14 (2000) Petitioner Exhibit 1073: Msaouel et al., Attenuated oncolytic Measles Virus strains as cancer therapeutics, 13(9) CURR. PHARM. BIOTECHNOL. 1732-41 (July 1, 2012) Petitioner Exhibit 1074: McDonald et al., A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer, 99 BREAST CANCER RESEARCH AND TREATMENT 177-184 (2006) Petitioner Exhibit 1075: Blechacz et al., Engineered Measles Virus as a Novel Oncolytic Viral Therapy System for Hepatocellular Carcinoma, 44(6) HEPATOLOGY 1465-77 (December 2006) Petitioner Exhibit 1076: Kaufmann et al., Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus, 133 JOURNAL OF INVESTIGATIVE DERMATOLOGY 1034-42 (2013) Petitioner Exhibit 1077: Jacobs et al., Vaccinia Virus Vaccines: Past, Present and Future, 84(1) ANTIVIRAL RES. 1-13 (October 2009) Petitioner Exhibit 1078: Senzer et al., Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma, 27(34) JOURNAL OF CLINICAL ONCOLOGY 5763-71 (December 1, 2009) Petitioner Exhibit 1079: Kelly and Russell, History of Oncolytic Viruses: Genesis to Genetic Engineering, 15(4) MOLECULAR THERAPY 651-659 (April 2007) Petitioner Exhibit 1080: Sinkovics and Horvath, Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers, 56 ARCH. IMMUNOL. THER. EXP. 3-59 (2008) Petitioner Exhibit 1081: Study Details for Clinical Trial NCT02272855 A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma, last updated September 26, 2018, available at: https://clinicaltrials.gov/ct2/show/NCT02272855 Petitioner Exhibit 1082: Study Details for Clinical Trial NCT02620423 Study of Pembrolizumab with REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma, last updated September 13, 2018, available at: https://clinicaltrials.gov/ct2/show/NCT02620423 Petitioner Exhibit 1083: Ahmed et al., Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy, 10 GENE THERAPY 1663-71 (2003) Petitioner Exhibit 1084: Simpson et al., Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control, 66(9) CANCER RES. 4835-42 (May 1, 2006) Petitioner Exhibit 1085: Pentcheva-Hoang et al., B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse, 21 IMMUNITY 401-413 (September 2004) Petitioner Exhibit 1086: Choi et al., Polymeric oncolytic adenovirus for cancer gene therapy, 219 JOURNAL OF CONTROLLED RELEASE 181-191 (2015) Petitioner Exhibit 1087: Croyle et al., PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum, 78(2) JOURNAL OF VIROLOGY 912-921 (January 2004) Petitioner Exhibit 1088: Tesfay et al., PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice, 87(7) JOURNAL OF VIROLOGY 3752-59 (April 2013) Petitioner Exhibit 1089: Lipson and Drake, Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma, 17(22) CLIN. CANCER RES. 6958-62 (November 2011) Petitioner Exhibit 1090: Ribas, Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab, 37(5) SEMINARS IN ONCOLOGY 450-454 (October 2010) Petitioner Exhibit 1091: Output from Biocompare search for CTLA-4 Antibodies (performed Nov. 24, 2021), available at https://www.biocompare.com/Search-Antibodies/?search=CTLA-4&said=0 Petitioner Exhibit 1092: Output from Antibodypedia search for CTLA-4 Antibodies (performed Nov. 24, 2021), available at https://www.antibodypedia.com/gene/19961/CTLA4 Petitioner Exhibit 1093: Output from antibodies-online.com search for CTLA-4 Antibodies (performed Nov. 24, 2021), available at https://www.antibodies-online.com/search.php#5qk9 Petitioner Exhibit 1094: Smith et al., Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix, 9(6) CANCER 1211-18 (November-December 1956) Petitioner Exhibit 1095: Asada, Treatment of Human Cancer with Mumps Virus, 34(6) CANCER 1907-28 (December 1974) Petitioner Exhibit 1096: International Search Report for International Patent Application No. PCT/FI2009/051025 Petitioner Exhibit 1097: International Search Report for International Patent Application No. PCT/EP2015/066263 Petitioner Exhibit 1098: Kleinpeter et al., Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition, 5(10) ONCOIMMUNOLOGY e1220467 (2016) Petitioner Exhibit 1099: Documents filed on July 9, 2018 in U.S. Patent Application Serial No. 16/068,830, including original application, preliminary amendment, application data sheet, search report, and transmittal form Petitioner Exhibit 1100: Ishikawa et al., STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity, 461 NATURE 788-792 (October 8, 2009)

Supplemental Search

Search for PTAB Motions

PTAB Analytics

TTAB Analytics

Basic Search

Filters

Party Search

Advanced

Selected Courts

Recently Selected Courts

Find PTAB Decisions

PTAB Analytics

Special PTAB Alerts

Orange Book

Directly Search Federal Courts

Search Trademark ...

Search millions of cases and get court filings, fast docket alerts, and case analytics.

Request a Demo or create your account.

Lawyer? Your firm may have a group account, ask us and we'll let you know.

Patent Owner

Petitioners

Keyboard shortcuts

Filtering / Searching the Docket

Interactive Timeline

Transgene v. Replimune Limited

PGR2022-00014 | Patent Trial and Appeal Board

Interested in this case?

Event:

Event:

Event:

Event:

Alert Sharing

STEP 2 of 2

Choose your membership type

Flat-Fee

Pay-As-You-Go Monthly

Add your payment information

Login or Join

Enter your corporate Email

Thousands of your peers are saving time and gaining a competitive advantage with Docket Alarm.

Join Docket Alarm to perform smarter legal research.

Download this document and millions of others instantly with a Docket Alarm membership.

Join Docket Alarm and start performing smarter legal research.

Start tracking this docket instantly with a Docket Alarm membership.

Join thousands of your peers and start performing smarter legal research.

STEP 1 of 2

Millions of Documents | 15 Seconds to Signup

Hi !

Welcome to Docket Alarm

Welcome to Docket Alarm!

Explore Litigation Insights andManage Your Cases

Reset Password

What is PACER?

Why do I need it?

What will I be charged?

Do other courts have fees?

Basic Free Access

Welcome

Thank you

Check Firm Account

Explore Litigation Insights and
Manage Your Cases